Eli Lilly's $2.6 billion agreement with ABL Bio focuses on developing therapeutics using the Grabody Platform for bispecific ...

Tuesday, November 18, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft ...

Blood-thinning drugs that doctors often prescribe interchangeably after procedures to reopen narrowed heart arteries don’t ...

Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain ...

Neurona Therapeutics, a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for disorders of the nervous system, today announced the appointment of Eduardo ...

Get the latest on S&P 500 healthcare stocks, top gainers/losers, sector news, major deals, and policy moves impacting investments.

Eli Lilly (LLY) drops CVS Health's (CVS) drug plan after the health insurer limited access to its obesity drug, Zepbound in favor of Novo's (NVO) Wegovy. Read more here.

Ovid Therapeutics announced it will name its president and chief operating officer Meg Alexander as its new CEO – replacing Jeremy Levin, effective January 1, 2026. She will also join the board of ...

Eli Lilly is dropping CVS Health's drug benefit plan for its employees after the healthcare conglomerate stopped covering the company's weight-loss drug in favor of Novo Nordisk's rival medication, ...

The new generation of obesity medications are inducing greater weight loss than any prior pharmacotherapy. There is discussion now about how to support fat loss while protecting lean mass.“Lean mass ...